![](https://static.biospace.com/dims4/default/668e852/2147483647/strip/true/crop/360x180+0+0/resize/200x100!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Flegacy%2FBioSpace-Assets%2F1E7BCCBB-F830-4AB1-AF1B-2BD0B6BE9027.png)
Genprex, Inc.
NEWS
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
JOBS
IN THE PRESS